Drug releasing coatings for medical devices

• US 9,314,552 B2
• Filed: 04/17/2015
• Issued: 04/19/2016
• Est. Priority Date: 11/20/2006
• Status: Active Grant

• Current Assignee: Lutonix, Inc. (Becton, Dickinson & Co)
• Original Assignee: Lutonix, Inc. (Becton, Dickinson & Co)
• Inventors: Wang, Lixiao
• Primary Examiner(s): ZISKA, SUZANNE E
• Application Number:
  US14/689,676
• Publication Number:
  US 20150217031A1
• Time in Patent Office: 368 Days
• US Class Current: 1/1
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/337 having four-membered rings, e.g. taxol
• CPC Class Codes: A61K 31/436 the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
• CPC Class Codes: A61L 2300/416 Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
• CPC Class Codes: A61L 2300/80 characterised by a special chemical form
• CPC Class Codes: A61L 2300/802 Additives, excipients, e.g. cyclodextrins, fatty acids, surfactants
• CPC Class Codes: A61L 29/16 Biologically active materials, e.g. therapeutic substances A61L29/048 takes precedence
• CPC Class Codes: A61L 31/08 Materials for coatings
• CPC Class Codes: A61L 31/16 Biologically active materials, e.g. therapeutic substances A61L31/047 takes precedence

Abstract

Medical device are provided for delivering a therapeutic agent to a tissue. The medical device has a layer overlying the exterior surface of the medical device. The layer contains a therapeutic agent and an additive. In certain embodiments, the additive has a hydrophilic part and a drug affinity part, wherein the drug affinity part is at least one of a hydrophobic part, a part that has an affinity to the therapeutic agent by hydrogen bonding, and a part that has an affinity to the therapeutic agent by van der Waals interactions. In embodiments, the additive is water-soluble. In further embodiments, the additive is at least one of a surfactant and a chemical compound, and the chemical compound has a molecular weight of from 80 to 750 or has more than four hydroxyl groups.

Claims

1. A medical device comprising:

a drug-releasing coating layer overlying an exterior surface of the medical device, wherein;

the medical device is a stent or a stent graft;

the drug-releasing coating layer comprises a hydrophobic therapeutic agent and a combination of additives comprising a first additive and a second additive;

the hydrophobic therapeutic agent is chosen from paclitaxel, rapamycin, daunorubicin, doxorubicin, lapachone, vitamin D2, vitamin D3, or combinations thereof;

the first additive is a PEG fatty ester chosen from PEG laurates, PEG oleates, PEG stearates, PEG glyceryl laurates, PEG glyceryl oleates, PEG glyceryl stearates, PEG sorbitan monolaurates, PEG sorbitan monooleates, PEG sorbitan stearates, PEG sorbitan laurates, PEG sorbitan oleates, PEG sorbitan palmitates, and combinations thereof; and

the second additive is chosen from sorbitol, sorbitan, xylitol, gluconolactone, lactobionic acid, and combinations thereof.

2. The medical device of claim 1, wherein the hydrophobic therapeutic agent is paclitaxel, rapamycin, or a combination thereof.

3. The medical device of claim 1, wherein the first additive is selected from the group consisting of PEG sorbitan monolaurates, PEG sorbitan monooleates, PEG sorbitan stearates, PEG sorbitan laurates, PEG sorbitan oleates, PEG sorbitan palmitates, and combinations thereof.

4. The medical device of claim 1, wherein the first additive is selected from the group consisting of PEG-20 sorbitan monolaurate, PEG-20 sorbitan monopalmitate, PEG-20 sorbitan monostearate, PEG-20 sorbitan monooleate, and combinations thereof.

5. The medical device of claim 1, wherein the first additive is a PEG sorbitan monolaurate.

6. The medical device of claim 5, wherein the PEG sorbitan monolaurate is PEG-20 sorbitan monolaurate.

7. The medical device of claim 1, wherein the first additive is a PEG sorbitan monooleate.

8. The medical device of claim 7, wherein the PEG sorbitan monooleate is PEG-20 sorbitan monooleate.

9. The medical device of claim 1, wherein the first additive is PEG-20 sorbitan monolaurate, PEG-20 sorbitan monooleate, or a combination thereof.

10. The medical device of claim 1, wherein the second additive is sorbitol, gluconolactone, or a combination thereof.

11. The medical device of claim 1, wherein the second additive is sorbitol.

12. The medical device of claim 1, wherein the second additive is gluconolactone.

13. The medical device of claim 1, wherein:

the hydrophobic therapeutic agent is paclitaxel;

the first additive is PEG-20 sorbitan monolaurate, PEG-20 sorbitan monooleate, or a combination thereof; and

the second additive is sorbitol, gluconolactone, or a combination thereof.

14. The medical device of claim 1, wherein:

the hydrophobic therapeutic agent is rapamycin;

the first additive is PEG-20 sorbitan monolaurate, PEG-20 sorbitan monooleate, or a combination thereof; and

the second additive is sorbitol, gluconolactone, or a combination thereof.

15. The medical device of claim 1, wherein:

the hydrophobic therapeutic agent is paclitaxel;

the first additive is PEG-20 sorbitan monolaurate; and

the second additive is sorbitol.

16. The medical device of claim 1, wherein:

the hydrophobic therapeutic agent is paclitaxel; and

the second additive is gluconolactone.

17. A medical device comprising:

a coating layer overlying an exterior surface of the medical device, wherein;

the medical device is a stent or a stent graft;

the coating layer comprises a hydrophobic therapeutic agent and at least one additive;

the hydrophobic therapeutic agent is chosen from paclitaxel, rapamycin, daunorubicin, doxorubicin, lapachone, vitamin D2, vitamin D3, and combinations thereof;

the at least one additive is chosen from PEG-20 sorbitan monolaurate, PEG-20 sorbitan monooleate, gluconolactone, and combinations thereof.

18. The medical device of claim 17, wherein:

the hydrophobic therapeutic agent is paclitaxel;

the at least one additive is PEG-20 sorbitan monolaurate.

19. The medical device of claim 17, wherein:

the hydrophobic therapeutic agent is paclitaxel;

the at least one additive is PEG-20 sorbitan monooleate.

20. The medical device of claim 17, wherein:

the hydrophobic therapeutic agent is paclitaxel;

the at least one additive is gluconolactone.